- Home
- SY vs ATAI Comparison
SY vs ATAI Comparison
Compare SY & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SY
- ATAI
- Stock Information
- Founded
- SY 2013
- ATAI 2018
- Country
- SY China
- ATAI Germany
- Employees
- SY N/A
- ATAI N/A
- Industry
- SY EDP Services
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- SY Technology
- ATAI Health Care
- Exchange
- SY Nasdaq
- ATAI Nasdaq
- Market Cap
- SY 482.1M
- ATAI 444.7M
- IPO Year
- SY 2019
- ATAI 2021
- Fundamental
- Price
- SY $4.05
- ATAI $4.57
- Analyst Decision
- SY Strong Buy
- ATAI Strong Buy
- Analyst Count
- SY 1
- ATAI 3
- Target Price
- SY $5.50
- ATAI $13.33
- AVG Volume (30 Days)
- SY 1.8M
- ATAI 6.3M
- Earning Date
- SY 08-15-2025
- ATAI 08-14-2025
- Dividend Yield
- SY 0.66%
- ATAI N/A
- EPS Growth
- SY N/A
- ATAI N/A
- EPS
- SY N/A
- ATAI N/A
- Revenue
- SY $197,807,588.00
- ATAI $2,309,000.00
- Revenue This Year
- SY $8.61
- ATAI $423.05
- Revenue Next Year
- SY $54.55
- ATAI N/A
- P/E Ratio
- SY N/A
- ATAI N/A
- Revenue Growth
- SY N/A
- ATAI 510.85
- 52 Week Low
- SY $0.66
- ATAI $1.03
- 52 Week High
- SY $6.28
- ATAI $4.74
- Technical
- Relative Strength Index (RSI)
- SY 47.11
- ATAI 70.54
- Support Level
- SY $3.45
- ATAI $3.60
- Resistance Level
- SY $4.15
- ATAI $4.23
- Average True Range (ATR)
- SY 0.45
- ATAI 0.33
- MACD
- SY -0.17
- ATAI -0.01
- Stochastic Oscillator
- SY 31.58
- ATAI 85.09
About SY So-Young International Inc. American Depository Shares
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.